MicroRNAs as disease specific diagnostic biomarkers for neoplastic aetiology-related and inflammatory-related pericardial fluid effusion

Abstract Background and aim Malignant involvement of the pericardium is seen in 1 to 20 percent autopsies patients with cancer. The most common metastatic tumor involving lung cancer [1]. We aimed distinguish origin pericardial fluid effusion (i.e. pericarditis vs cancer) based on miRNAs expression peripheral blood plasma. Method 8 hospitalized for collection neoplastic aetiology (lung cancer). Control group includes inflammatory aetiology. Plasma RNA was extracted by mirVANAPARISKit quality assessed fluorometric assay. GEP analysis performed using Clariom D pico chips, analysed Affymetrix platform. Statistical TAC software. Additional analyses were R Signal information obtained from output. following tests log2 transformed data all comparison groups (A-F). FDR correction, logistic regression, Mann-whitney t-test used depending variables. calculated Area under curve ROCp package. Scores ranging 0 1. Co-expression identify genes authentically expressed Spearman correlation (cutoff = 0.9, Rpval 0.05). In order targets DE we our wizbionet package previously developed pipelines [2,3]. target screening multimiR package, selecting top 20% predictions available databases. Results analyzed mature versions, if miR identified as pre-miR generated -3p -5p version it. also screened DisgeNet database associated pericarditis, 2823 157 such genes. After identification aggregation, summarization how many overall IS are regulated each miRNA. Additionally miRNAs. MiR-5695, miR-4446-5p, miR-572, miR-3131 miR-4784 found significantly differentially plasma malignancy compared pericarditis. MiR-22-3p, miR-642a, miR-6771, miR-140-3p, miR660-5p Importantly, miR-500b, miR-5188, miR-490, miR-24-3p, miR-383-3p promising diagnostic biomarkers inflammatory-related effusion. Conclusions For first time results indicate power circulating having excessive due different etiologies. Funding Acknowledgement Type funding sources: None. Figure 1Figure 2